Technical Analysis for TPST - Tempest Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -4.14% | |
| Weak + Overbought | Other | -4.14% | |
| Overbought Stochastic | Strength | -4.14% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Possible NR7 | about 15 hours ago |
| Fell Below 20 DMA | about 17 hours ago |
| 20 DMA Support | about 20 hours ago |
| Down 3% | about 20 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
Tempest Therapeutics, Inc. Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecules that combine targeted and immune-mediated mechanisms with the potential to treat various tumors. The company's two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa. Its TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study agents as monotherapies and in combination with other approved agents. The company is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. The company is headquartered in South San Francisco, California. Tempest Therapeutics Inc. operates as a subsidiary of Inception Sciences, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Tumor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.0 |
| 52 Week Low | 0.17 |
| Average Volume | 1,006,921 |
| 200-Day Moving Average | 2.99 |
| 50-Day Moving Average | 3.67 |
| 20-Day Moving Average | 3.47 |
| 10-Day Moving Average | 3.56 |
| Average True Range | 0.28 |
| RSI (14) | 46.24 |
| ADX | 14.55 |
| +DI | 22.25 |
| -DI | 18.70 |
| Chandelier Exit (Long, 3 ATRs) | 3.35 |
| Chandelier Exit (Short, 3 ATRs) | 3.90 |
| Upper Bollinger Bands | 3.84 |
| Lower Bollinger Band | 3.10 |
| Percent B (%b) | 0.5 |
| BandWidth | 21.34 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0291 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.64 | ||||
| Resistance 3 (R3) | 3.64 | 3.60 | 3.61 | ||
| Resistance 2 (R2) | 3.60 | 3.55 | 3.59 | 3.60 | |
| Resistance 1 (R1) | 3.53 | 3.53 | 3.51 | 3.53 | 3.59 |
| Pivot Point | 3.49 | 3.49 | 3.48 | 3.48 | 3.49 |
| Support 1 (S1) | 3.42 | 3.44 | 3.40 | 3.42 | 3.35 |
| Support 2 (S2) | 3.38 | 3.42 | 3.37 | 3.34 | |
| Support 3 (S3) | 3.31 | 3.38 | 3.33 | ||
| Support 4 (S4) | 3.31 |
